RELUMINATE
Alkermes Pharma Ireland Limited
| Research |
OneLook
Acronym Finder
|
| Serial Number | 87486030 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Attorney Name | Norm J. Rich |
| Attorney Docket Number | 029318-2742 |
| Law Office Assigned | N70 |
| Employee Name | INGRAM, KYLE G |
Timeline
| 2017-06-13 | Application Filed |
| 2018-03-27 | Published for Opposition |
| 2018-05-22 | Location: INTENT TO USE SECTION |
| 2019-10-30 | Status: Live/Pending |
| 2019-11-01 | Transaction Date |
Trademark Applicants & Owners
| Owner: |  Alkermes Pharma Ireland Limited |
| Address | CONNAUGHT HOUSE 1 BURLINGTON ROAD DUBLIN IE |
| Legal Entity Type | Corporation |
| Legal Entity State | IE |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Prescription pharmaceutical preparations for the treatment of diseases mediated by an opioid receptor, namely, major depressive disorder, chronic depression, severe unipolar recurrent major depressive episodes, dysthymic disorder, depressive neurosis and neurotic depression, melancholic depression, atypical depression, reactive depression, treatment resistant depression, seasonal affective disorder and pediatric depression, premenstrual syndrome, premenstrual dysphoric disorder, hot flashes, bipolar disorders or manic depression, bipolar I disorder, bipolar II disorder and cyclothymic disorder, anxiety, post-traumatic stress disorder, obsessive compulsive disorder and borderline personality disorder |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| NEW APPLICATION ENTERED IN TRAM | 2017-06-16 | 1 NWAP I:Incoming Correspondence |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2017-06-19 | 2 NWOS I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2017-07-21 | 3 DOCK D:Assigned to Examiner |
| NON-FINAL ACTION WRITTEN | 2017-08-04 | 4 CNRT R:Renewal |
| NON-FINAL ACTION E-MAILED | 2017-08-04 | 5 GNRT F:First Action |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2017-08-04 | 6 GNRN O:Outgoing Correspondence |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2018-02-02 | 7 TROA I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2018-02-02 | 8 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2018-02-03 | 9 TEME I:Incoming Correspondence |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2018-02-20 | 10 CNSA P: |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2018-03-07 | 11 NONP E:E-Mail |
| PUBLISHED FOR OPPOSITION | 2018-03-27 | 12 PUBO A:Allowance for Publication |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2018-03-27 | 13 NPUB E:E-Mail |
| NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2018-05-22 | 14 NOAM E:E-Mail |
| TEAS EXTENSION RECEIVED | 2018-08-31 | 15 EEXT I:Incoming Correspondence |
| EXTENSION 1 FILED | 2018-08-31 | 16 EXT1 S: |
| EXTENSION 1 GRANTED | 2018-08-31 | 17 EX1G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2018-09-04 | 18 EXRA E:E-Mail |
| TEAS EXTENSION RECEIVED | 2019-05-20 | 19 EEXT I:Incoming Correspondence |
| EXTENSION 2 FILED | 2019-05-20 | 20 EXT2 S: |
| EXTENSION 2 GRANTED | 2019-05-20 | 21 EX2G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2019-05-22 | 22 EXRA E:E-Mail |
| TEAS EXTENSION RECEIVED | 2019-10-30 | 23 EEXT I:Incoming Correspondence |
| EXTENSION 3 FILED | 2019-10-30 | 24 EXT3 S: |
| EXTENSION 3 GRANTED | 2019-10-30 | 25 EX3G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2019-11-01 | 26 EXRA E:E-Mail |
| TEAS EXTENSION RECEIVED | 2020-04-20 | 27 EEXT I:Incoming Correspondence |
| EXTENSION 4 FILED | 2020-04-20 | 28 EXT4 S: |
| EXTENSION 4 GRANTED | 2020-04-20 | 29 EX4G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2020-04-22 | 30 EXRA E:E-Mail |
| TEAS EXTENSION RECEIVED | 2020-10-29 | 31 EEXT I:Incoming Correspondence |
| CASE ASSIGNED TO INTENT TO USE PARALEGAL | 2020-11-06 | 32 AITU A:Allowance for Publication |
| EXTENSION 5 FILED | 2020-10-29 | 33 EXT5 S: |
| EXTENSION 5 GRANTED | 2020-11-06 | 34 EX5G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2020-11-07 | 35 EXRA E:E-Mail |
| ABANDONMENT - NO USE STATEMENT FILED | 2021-06-28 | 36 ABN6 S: |
| ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | 2021-06-28 | 37 MAB6 E:E-Mail |
Similar Marks
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 RELUMINATE 87486030 not registered Live/Pending |
Alkermes Pharma Ireland Limited 2017-06-13 |
 RELUMINATE 77035309 3271362 Live/Registered |
JCB Enterprises, Inc. 2006-11-02 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 